The DOI matches its Crossref record; 267 of the 268 references it cites were found in a registry or an index.
Natural killer cells in cancer biology and therapy
Open accessAbstract
The tumor microenvironment is highly complex, and immune escape is currently considered an important hallmark of cancer, largely contributing to tumor progression and metastasis. Named for their capability of killing target cells autonomously, natural killer (NK) cells serve as the main effector cells toward cancer in innate immunity and are highly heterogeneous in the microenvironment. Most current treatment options harnessing the tumor microenvironment focus on T cell-immunity, either by promoting activating signals or suppressing inhibitory ones. The limited success achieved by T cell immunotherapy highlights the importance of developing new-generation immunotherapeutics, for example utilizing previously ignored NK cells. Although tumors also evolve to resist NK cell-induced cytotoxicity, cytokine supplement, blockade of suppressive molecules and genetic engineering of NK cells may overcome such resistance with great promise in both solid and hematological malignancies. In this review, we summarized the fundamental characteristics and recent advances of NK cells within tumor immunometabolic microenvironment, and discussed potential application and limitations of emerging NK cell-based therapeutic strategies in the era of presicion medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to this difference in cytokine secretion profile, NK cells have the potential to be developed as “off-the-shelf” CAR products with a lower risk of inducing CRS compared to CAR-T cells.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [267]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, NK cells do not produce IL-1 and IL-6, which are key cytokines involved in the development of CRS [266, 267].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [267]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Meyaard, L., de Vries, A.-R. V. D. V., Ruiter, T. E.-D., Lanier, L. L., Phillips, J. H., & Clevers, H. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.1.107 · Cited by 43
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“Background The diversity of infiltrating stromal cells occurring in human cancers exceeds 30 distinct subgroups, reflecting the huge complexity of the tumor microenvironment (TME), thereby deeply affecting the treatment option for each patient [1].”
BackgroundRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270 · cited 1×
“However, the specific role of NK cells remains controversial and largely depends on distinct cancer types [109].”
BackgroundEmerging Biological Principles of Metastasis
Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,067 · cited 1×
“Apart from primary tumor proliferation, metastasis remains lethal, accounting for the majority of cancerassociated deaths, and invasion-metastasis cascade is largely attributable to the immune escape [136].”
Background
Research works printed but not linked: 3
- Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, Castriconi R, Vitale M, Pende D, Sivori S, Millo R, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol. 1999;29:3148–59. · doi:10.1002/(sici)1521-4141(199910)29:10<3148::aid-immu3148>3.0.co;2-l
- Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK cells. Eur J Immunol. 2002;32:879–84. · doi:10.1002/1521-4141(200203)32:3<879::aid-immu879>3.0.co;2-2
- Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunol. 2018;18:671–88. · DOI · Paper page
Cited by
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
“H3K27 trimethylation inhibition by EZH2 inhibitors (UNC1999 and EPZ005687) enhanced the expression of genes associated with NK cell cytotoxic function, such as Klrk1 (encoding NKG2D), and the in vitro cytotoxic activity of NK cells.(363) In HCC, EZH2 inhibition with a small molecule (GSK126) may simultaneously upregul…”
BackgroundTumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
“Therefore, enhancing the NK cells activity within the TME is a promising direction in cancer therapy [153, 154] Fig.”
BackgroundCurrent Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
Heipertz, E. L., Zynda, E. R., Stav-Noraas, T. E., Hungler, A. D., Boucher, S. E., Kaur, N., & Vemuri, M. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.732135 · Cited by 211
“Most clinical trials of NK cells require large numbers of cells for infusion, ranging from 5×10(6) to 1×10(8) CD3CD56 NK cells per kilogram body weight (5).”
BackgroundInfluentialLiu, K., Zhang, X., Xie, L., Deng, M., Chen, H., Song, J., Long, J., Li, X., & Luo, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105373 · Cited by 198
Metadata
- Authors
- Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Jiang, Yi-Zhou
- Shao, Zhi-Ming
- Venue
- Molecular Cancer
- Published
- 2020-08-06
- Volume
- 19
- Issue
- 1
- Pages
- 120-120
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC7409673
- OpenAlex
- W3046958019
- Cited by
- 863
- References
- 268
- Citations by year
- 2026: 77 · 2025: 199 · 2024: 219 · 2023: 170 · 2022: 122 · 2021: 70 · 2020: 5
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81572583, 81874112, 81874113, 81502278, 81922048)
- Shanghai Education Development Foundation (17CG01)
- Fudan University
- Shanghai Municipal Education Commission (17CG01)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- natural killer cells, tumor microenvironment, immune evasion, NK cell therapy, NK cell resistance, tumor immunometabolism, NK cell engineering, innate immunity, hematologic malignancies, solid tumors, precision medicine
- MeSH terms
- Animals, Disease Susceptibility, Energy Metabolism, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Neoplasms, Signal Transduction, Biomarkers, Disease Progression, Disease Management, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural killer cells in cancer biology and therapy. https://app.cochat.ai/papers/10.1186/s12943-020-01238-x
- The paper
- Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020). Natural killer cells in cancer biology and therapy. Molecular Cancer. https://doi.org/10.1186/s12943-020-01238-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.